Clinically, CBL mutations were associated with a more proliferative phenotype evidenced by increased bone marrow blasts, leukocytosis and splenomegaly, similar to other RAS pathway mutations such as KRAS, NRAS and PTPN11. Here, NRAS is linked to Increased total leukocyte count.